Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $43
Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $43
派珀·桑德勒維持對Supernus Pharmicals的增持,將目標股價提高至43美元
Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $42 to $43.
派珀·桑德勒分析師戴維·阿姆塞勒維持Supernus Pharmicals(納斯達克股票代碼:SUPN)增持 “增持”,並將目標股價從42美元上調至43美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。